Prominent Moroccan presence at the 26th EURETINA Congress in Vienna

Prominent Moroccan presence in international scientific forums

As part of a new international scientific milestone that strengthens the position and Moroccan medical expertise on the global stage, Dr. Salah Arnaou, a native of Nador, represented the Kingdom at the 26th European Society of Retina Specialists (EURETINA) Congress. These major events were held in the Austrian capital, Vienna, from October 1 to 4, 2026.

A global platform for expertise exchange and continuing education

The (VIECON) congress center hosted this prominent scientific event, organized annually by the European Society of Retina Specialists. The event provided an exceptional opportunity for the Moroccan participant and other doctors to enhance their continuing education, bridge communication, and exchange high-level expertise with the world’s leading retina and vitreoretinal surgery specialists.

A powerful start with thousands of experts from various continents

The congress began with an opening address by the society’s president, Professor Nicole Eter. The forum saw the participation of nearly 10,000 specialists from different continents, reflecting the significant importance of ophthalmology and eye surgery issues at the international level.

A rich scientific program with the latest clinical and technical innovations

The scientific program for this session was notable for its richness and diversity, featuring intensive sessions that addressed the latest clinical and innovative technical developments in the diagnosis and treatment of retinal diseases. The program aimed to provide participating doctors the chance to keep pace with the latest global technological and therapeutic revolutions.

New regulatory horizons for drug development

Beyond the purely surgical and technical aspects, the congress included a pivotal symposium that shed light on the mechanisms for regulating and developing ophthalmological drugs within the European Union. The session witnessed significant participation from representatives of the European Medicines Agency (EMA), opening new horizons for researchers and doctors to understand modern regulatory frameworks for medical drug development.